

Kenya

Support for Vaccine: Pneumococcal conjugate vaccine (PCV)

This Decision Letter sets out the Programme Terms of a Programme

1. Country: Kenya

2. Vaccine grant number: KEN-PCV-R

3. Date of Decision Letter: 28 September 2021

4. Date of the Partnership Framework Agreement: 25 November 2014

5. Programme title: New Vaccine Support (NVS), Pneumococcal conjugate vaccine (PCV), Routine

6. Vaccine type: Pneumococcal conjugate vaccine (PCV)

7. Requested product presentation and formulation of vaccine:

PCV10, 4 doses/vial, liquid

PCV10, 5 doses/vial, liquid

8. Programme duration:¹ 2010-2022

9. Programme Budget (indicative):²³ (subject to the terms of the Partnership Framework Agreement, if applicable)

	2010-2020	2021	2022	2023	2024	2025	Total ²
Programme Budget(US\$)	227.302.578	11.518.105	7.293.518	-	-	-	246.114.200

10. Vaccine introduction grant:

Approval		
Year	Grant number	Amount (US\$)

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

Starting January 2020, a separate Decision Letter for devices only, including historical value of devices will be discontinued. Vaccine programme decision letters issued since January 2020 contain associated devices, however devices in relation to years prior to 2020 are no longer included in decision letters.

³ This is the amount that Gavi has approved.

2008	KEN-PCV-R-VIG-MOH	443.500
------	-------------------	---------

11. Product switch grant:

Approval		
Year	Grant number	Amount (US\$)
2018	KEN-PCV-R-PSG	8.929
2018	KEN-PCV-R-PSG-UNIC	370.531

12. Indicative annual amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2010-2020	2021	2022
Number of vaccine doses	-	3.679.200	3.508.000
Number of AD syringes	-	3.682.800	3.572.800
Number of re-constitution syringes	-	-	-
Number of safety boxes	-	40.500	39.300
Annual Amounts (US\$)	227.302.578	11.518.105	7.293.518

13. Procurement agency: UNICEF Supply Division. The Country shall release its co-financing payments each year to UNICEF Supply Division.

14. Self-procurement:

Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:	Preparatory transition				
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2021/2022	2022/2023	2023/2024	2024/2025	2025/2026
Number of vaccine doses	396.400	523.250	-	-	-
Number of AD syringes	396.500	533.000	-	-	-
Number of re-constitution syringes	-	-	-	-	-

Number of safety boxes	4.375	5.875	-	-	-
Value of vaccine doses (US\$)	1.209.020	1.046.500	-	-	-
Total co-financing payments (US\$) (including freight)	1.235.189	1.087.905	-	-	-

16. Operational support for campaigns:

Not applicable

17. Additional Reporting Requirements:

Reports and other information :	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> • vaccine stock levels including buffer stock, by end of March; • number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. • Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March</p> <p>15 May</p>
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Gavi Secretariat</p>

18. Financial clarifications:

Not applicable

19. Other conditions:

Not applicable